Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A retinotopic wiring principle of the human brain.

bioRxiv : the preprint server for biology·2026
Same author

Bioimage analysis for multiplexed FUCCI acquisitions powered by deep learning.

Npj imaging·2026
Same author

Baseline characteristics of a diagnostically defined early psychosis cohort entering supported employment and education: findings from the SEEearly trial.

European archives of psychiatry and clinical neuroscience·2026
Same author

Aniridia-associated keratopathy: Clinical and molecular mechanisms of disease progression and emerging therapeutic targets.

Acta ophthalmologica·2026
Same author

Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC.

NPJ precision oncology·2025
Same author

Reperfusion failure after successful thrombectomy of large vessel occlusion stroke: clinical and imaging evidence.

Frontiers in neurology·2025

Related Experiment Video

Updated: Jun 5, 2026

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
13:18

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

[Response and remission in schizophrenic subjects].

J Zimmermann1, A Wolter, N R Krischke

  • 1Karl-Jaspers-Klinik, Psychiatrieverbund Oldenburger Land gGmbH, Bad Zwischenahn, Deutschland. joerg.zimmermann@karl-jaspers-klinik.de

Der Nervenarzt
|January 12, 2011
PubMed
Summary

Schizophrenia treatment shows lower response and remission rates in real-world inpatient settings than in clinical trials. This highlights the chronic nature of schizophrenia and the need for improved long-term care strategies.

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Related Experiment Videos

Last Updated: Jun 5, 2026

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
13:18

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Neuroscience

Context:

  • Investigates symptom reduction during acute inpatient treatment and long-term improvement in schizophrenia.
  • Examines re-hospitalization rates in a naturalistic setting.
  • Utilizes established criteria for response and remission.

Purpose:

  • To detail symptom reduction (response) and long-term improvement (remission) in schizophrenia patients.
  • To assess the rate of re-hospitalizations in a cohort of 183 patients.
  • To compare real-world treatment outcomes with findings from randomized controlled trials.

Summary:

  • A naturalistic study of 183 schizophrenia patients found response rates of 63.9% at a 20% PANSS score reduction.
  • Only 10.3% of patients achieved remission within a 1-year follow-up, and 43.9% required re-hospitalization.
  • Schizophrenia response and remission rates were significantly lower than in previous controlled trials.

Impact:

  • Findings suggest the chronic course of schizophrenia is more prevalent in daily inpatient care than previously reported.
  • Highlights a discrepancy between controlled trial outcomes and real-world clinical practice for schizophrenia.
  • Indicates a need for revised or enhanced long-term treatment strategies for schizophrenia management.